What is Apnimed planning with its IPO and FDA sleep apnea pill?

Apnimed is preparing for an initial public offering to fund the launch of its drug for obstructive sleep apnea, which is still under FDA review. The IPO would provide capital for commercialization if approval is granted, positioning Apnimed as a leader in pharmacologic treatment within a market dominated by device-based solutions.